115 related articles for article (PubMed ID: 32918658)
1. Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients.
Mao D; Hachem H; Chang H; Dima D; Dower J; Wismer M; Erban JK; Freund KM; Parsons SK
Breast Cancer Res Treat; 2020 Dec; 184(3):665-674. PubMed ID: 32918658
[TBL] [Abstract][Full Text] [Related]
2. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer.
Nekhlyudov L; Li L; Ross-Degnan D; Wagner AK
Breast Cancer Res Treat; 2011 Nov; 130(2):681-9. PubMed ID: 21842245
[TBL] [Abstract][Full Text] [Related]
3. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.
Hershman DL; Shao T; Kushi LH; Buono D; Tsai WY; Fehrenbacher L; Kwan M; Gomez SL; Neugut AI
Breast Cancer Res Treat; 2011 Apr; 126(2):529-37. PubMed ID: 20803066
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
5. Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women--an Asian population-based study.
Hsieh KP; Chen LC; Cheung KL; Chang CS; Yang YH
PLoS One; 2014; 9(2):e87027. PubMed ID: 24586261
[TBL] [Abstract][Full Text] [Related]
6. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
[TBL] [Abstract][Full Text] [Related]
7. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy.
Dispinzieri M; La Rocca E; Meneghini E; Fiorentino A; Lozza L; Di Cosimo S; Gennaro M; Cosentino V; Sant M; Pignoli E; Valdagni R; Bonfantini F; De Santis MC
Med Oncol; 2018 Jun; 35(7):107. PubMed ID: 29907919
[TBL] [Abstract][Full Text] [Related]
9. Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
Saraf A; Tahir I; Hu B; Dietrich AW; Tonnesen PE; Sharp GC; Tillman G; Roeland EJ; Nipp RD; Comander A; Peppercorn J; Fintelmann FJ; Jimenez RB
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):94-103. PubMed ID: 37506979
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer.
He W; Zeng E; Sjölander A; Hübbert L; Hedayati E; Czene K
JAMA Netw Open; 2023 Jul; 6(7):e2323752. PubMed ID: 37459096
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
He W; Fang F; Varnum C; Eriksson M; Hall P; Czene K
J Clin Oncol; 2015 Jul; 33(20):2262-9. PubMed ID: 26033800
[TBL] [Abstract][Full Text] [Related]
12. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
13. Clinical consultations and investigations before and after discontinuation of endocrine therapy in women with primary breast cancer.
Lopez D; Kemp-Casey A; Saunders C; Roughead E; Boyle F; Bulsara M; Preen D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765859
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant hormonal therapy use among women with ductal carcinoma in situ.
Livaudais JC; Hwang ES; Karliner L; Nápoles A; Stewart S; Bloom J; Kaplan CP
J Womens Health (Larchmt); 2012 Jan; 21(1):35-42. PubMed ID: 21902542
[TBL] [Abstract][Full Text] [Related]
15. Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).
Bluethmann SM; Alfano CM; Clapp JD; Luta G; Small BJ; Hurria A; Cohen HJ; Sugarman S; B Muss H; Isaacs C; Mandelblatt JS
Breast Cancer Res Treat; 2017 Oct; 165(3):677-686. PubMed ID: 28653250
[TBL] [Abstract][Full Text] [Related]
16. Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database.
Buszek SM; Lin HY; Bedrosian I; Tamirisa N; Babiera GV; Shen Y; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):795-802. PubMed ID: 31377160
[TBL] [Abstract][Full Text] [Related]
17. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
He W; Smedby KE; Fang F; Olsson H; Margolin S; Hall P; Czene K
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28423398
[TBL] [Abstract][Full Text] [Related]
18. Association between nociplastic pain and premature endocrine therapy discontinuation in breast cancer patients.
Joyce E; Carr G; Wang S; Brummett CM; Kidwell KM; Henry NL
Breast Cancer Res Treat; 2023 Jan; 197(2):397-404. PubMed ID: 36371776
[TBL] [Abstract][Full Text] [Related]
19. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
